MCID: ACT134
MIFTS: 59

Acute Liver Failure

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Acute Liver Failure

MalaCards integrated aliases for Acute Liver Failure:

Name: Acute Liver Failure 58 54 37
Fulminant Hepatic Failure 58 36 29 6
Acute Hepatic Failure 58 6
Hepatic Failure Fulminant 54
Liver Failure, Acute 71
Liver Failure Acute 54

Characteristics:

Orphanet epidemiological data:

58
acute liver failure
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare hepatic diseases


Summaries for Acute Liver Failure

KEGG : 36 Fulminant hepatic failure (FHF) is a life-threatening condition characterized by the rapid deterioration of liver functions and hepatic encephalopathy. FHF is with the basic definition of the onset of hepatic encephalopathy within 8 weeks of the appearance of the first symptoms like jaundice, fever, nausea, and vomiting. The prothrombin time is prolonged by 4-6 seconds or more. While the etiologies of FHF are multiple and varied, viral hepatitis is the most frequent cause. Around 40-60% of patients with FHF are thought to be due to some viral infection. The prognosis is dependent on several factors, including the underlying cause of liver failure. For instance, it is well known that the spontaneous recovery rates from FHF from such etiologies as hepatitis A and acetaminophen toxicity are high, whereas those same rates for other types of viral hepatitis and idiosyncratic drug reactions are quite low. Identification of the cause of FHF is important because some causes have specific treatment interventions or antidotes. Specific therapies include N-acetylcysteine for acetaminophen overdose, and acyclovir for herpesvirus infection. Different therapeutic options such as complete exchange blood transfusion, corticosteroids, and plasma pheresis, have been tried. However, the overall prognosis for patients with FHF is quite poor, with survival rates usually reported between 10% and 30% without liver transplantation.

MalaCards based summary : Acute Liver Failure, also known as fulminant hepatic failure, is related to infantile liver failure syndrome and mitochondrial dna depletion syndrome 6. An important gene associated with Acute Liver Failure is RINT1 (RAD50 Interactor 1). The drugs Prednisolone and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include Liver, bone marrow and brain, and related phenotypes are hepatitis and elevated hepatic transaminase

Wikipedia : 74 Acute liver failure is the appearance of severe complications rapidly after the first signs (such as... more...

Related Diseases for Acute Liver Failure

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 3
Infantile Liver Failure Syndrome Acute Liver Failure

Diseases related to Acute Liver Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 686)
# Related Disease Score Top Affiliating Genes
1 infantile liver failure syndrome 32.1 RINT1 NBAS
2 mitochondrial dna depletion syndrome 6 32.0 POLG2 POLG
3 hepatitis a 31.7 GPT F2 ALB
4 paracetamol poisoning 31.0 GC F2
5 hepatitis e 30.9 GPT F2 ALB
6 liver disease 30.8 SLC17A5 POLG HGF GPT F2 ALB
7 hepatic coma 30.8 TSPO GPT F2 ALB
8 viral hepatitis 30.8 SLC17A5 GPT F2 ALB
9 autoimmune hepatitis 30.6 SLC17A5 GPT F2 ALB
10 drug-induced hepatitis 30.6 GPT ALB
11 hepatorenal syndrome 30.5 GPT F2 ALB
12 exanthem 30.4 GPT F2 ALB
13 hepatitis b 30.4 SLC17A5 GPT F2 ALB
14 scrub typhus 30.3 SLC17A5 GPT
15 hellp syndrome 30.3 SLC17A5 GPT F2
16 portal hypertension 30.3 GPT F2 ALB
17 dengue hemorrhagic fever 30.3 GPT F2 ALB
18 cholestasis 30.3 SLC17A5 GPT F2 ALB
19 lactic acidosis 30.2 POLG2 POLG GPT F2
20 acute kidney failure 30.2 HGF GPT F2 ALB
21 inherited metabolic disorder 30.2 GPT F2 ALB
22 non-a-e hepatitis 30.2 F2 ALB
23 cholangitis 30.1 GPT F2 ALB
24 hepatic encephalopathy 30.1 TSPO SLC17A5 GPT GC F2 ALB
25 drug allergy 30.1 GPT ALB
26 hepatitis d 30.1 GPT F2
27 bilirubin metabolic disorder 30.1 SLC17A5 GPT F2 ALB
28 peliosis hepatis 30.1 GPT F2
29 cholecystitis 30.1 GPT F2 ALB
30 liver cirrhosis 30.0 SLC17A5 HGF GPT F2 ALB
31 hepatic infarction 30.0 GPT F2 ALB
32 reye syndrome 30.0 GPT F2 ALB
33 hemosiderosis 29.9 GPT ALB
34 sclerosing cholangitis 29.9 GPT F2 ALB
35 metabolic acidosis 29.9 POLG2 GPT F2 ALB
36 bronchopneumonia 29.9 GPT ALB
37 mitral valve insufficiency 29.9 F2 ALB
38 cardiac tamponade 29.9 F2 ALB
39 mitochondrial dna depletion syndrome 3 29.8 POLG2 POLG
40 splenic infarction 29.8 GPT F2 ALB
41 granulomatous hepatitis 29.8 GPT ALB
42 tricuspid valve insufficiency 29.8 GPT F2 ALB
43 alcohol use disorder 29.8 SLC17A5 GPT ALB
44 anuria 29.8 F2 ALB
45 papilledema 29.8 F2 ALB
46 babesiosis 29.8 GPT ALB
47 ascending cholangitis 29.8 GPT F2 ALB
48 volvulus of midgut 29.7 GPT F2 ALB
49 pericardial effusion 29.7 GPT F2 ALB
50 primary biliary cholangitis 29.7 SLC17A5 GPT F2 ALB

Graphical network of the top 20 diseases related to Acute Liver Failure:



Diseases related to Acute Liver Failure

Symptoms & Phenotypes for Acute Liver Failure

Human phenotypes related to Acute Liver Failure:

58 31 (show top 50) (show all 51)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0012115
2 elevated hepatic transaminase 58 31 hallmark (90%) Very frequent (99-80%) HP:0002910
3 jaundice 58 31 hallmark (90%) Very frequent (99-80%) HP:0000952
4 hepatocellular necrosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001404
5 hypotension 58 31 frequent (33%) Frequent (79-30%) HP:0002615
6 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
7 hypoglycemia 58 31 frequent (33%) Frequent (79-30%) HP:0001943
8 slurred speech 58 31 frequent (33%) Frequent (79-30%) HP:0001350
9 thrombocytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001873
10 bruising susceptibility 58 31 frequent (33%) Frequent (79-30%) HP:0000978
11 hyperammonemia 58 31 frequent (33%) Frequent (79-30%) HP:0001987
12 prolonged prothrombin time 58 31 frequent (33%) Frequent (79-30%) HP:0008151
13 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
14 confusion 58 31 frequent (33%) Frequent (79-30%) HP:0001289
15 adrenal insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0000846
16 drowsiness 58 31 frequent (33%) Frequent (79-30%) HP:0002329
17 agitation 58 31 frequent (33%) Frequent (79-30%) HP:0000713
18 nausea 58 31 frequent (33%) Frequent (79-30%) HP:0002018
19 mood changes 58 31 frequent (33%) Frequent (79-30%) HP:0001575
20 reduced factor vii activity 58 31 frequent (33%) Frequent (79-30%) HP:0008169
21 hepatic periportal necrosis 58 31 frequent (33%) Frequent (79-30%) HP:0002614
22 increased factor viii activity 58 31 frequent (33%) Frequent (79-30%) HP:0030977
23 reduced factor x activity 58 31 frequent (33%) Frequent (79-30%) HP:0008321
24 reduced coagulation factor v activity 58 31 frequent (33%) Frequent (79-30%) HP:0003225
25 depressivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0000716
26 ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001251
27 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
28 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
29 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
30 skin rash 58 31 occasional (7.5%) Occasional (29-5%) HP:0000988
31 intracranial hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002170
32 encephalopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001298
33 coma 58 31 occasional (7.5%) Occasional (29-5%) HP:0001259
34 pain insensitivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0007021
35 acute kidney injury 58 31 occasional (7.5%) Occasional (29-5%) HP:0001919
36 deep venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002625
37 hyperventilation 58 31 occasional (7.5%) Occasional (29-5%) HP:0002883
38 incoordination 58 31 occasional (7.5%) Occasional (29-5%) HP:0002311
39 acidosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001941
40 cerebral edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0002181
41 hypocapnia 58 31 occasional (7.5%) Occasional (29-5%) HP:0012417
42 shock 58 31 occasional (7.5%) Occasional (29-5%) HP:0031273
43 euphoria 58 31 occasional (7.5%) Occasional (29-5%) HP:0031844
44 alkalosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001948
45 seizure 31 occasional (7.5%) HP:0001250
46 seizures 58 Occasional (29-5%)
47 abnormal bleeding 58 Occasional (29-5%)
48 abnormal pattern of respiration 58 Frequent (79-30%)
49 functional respiratory abnormality 58 Frequent (79-30%)
50 hepatic necrosis 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Acute Liver Failure:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.61 ALB F2 GC NBAS POLG POLG2
2 mortality/aging MP:0010768 9.28 ALB F2 HGF NBAS POLG POLG2

Drugs & Therapeutics for Acute Liver Failure

Drugs for Acute Liver Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
2 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Norepinephrine Approved Phase 4 51-41-2 439260
7
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
10 Anti-Inflammatory Agents Phase 4
11 Gastrointestinal Agents Phase 4
12 Hormone Antagonists Phase 4
13 Hormones Phase 4
14 glucocorticoids Phase 4
15 Methylprednisolone Acetate Phase 4
16 Neuroprotective Agents Phase 4
17 Antineoplastic Agents, Hormonal Phase 4
18 Antiemetics Phase 4
19 Liver Extracts Phase 4
20 Anti-Bacterial Agents Phase 4
21 Antibiotics, Antitubercular Phase 4
22 Pharmaceutical Solutions Phase 4
23
Formaldehyde Approved, Vet_approved Phase 2, Phase 3 50-00-0 712
24
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
25
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492 6473866
26
Phenylacetic acid Approved Phase 2 103-82-2 999
27
Pentoxifylline Approved, Investigational Phase 1, Phase 2 6493-05-6 4740
28
Aspartic acid Approved, Nutraceutical Phase 2 56-84-8 5960
29
Ornithine Approved, Nutraceutical Phase 2 70-26-8, 3184-13-2 6262
30 Immunosuppressive Agents Phase 1, Phase 2
31
Bilirubin Phase 2 635-65-4 5280352
32 Vasoconstrictor Agents Phase 2
33 Neurotransmitter Agents Phase 2
34 N-Methylaspartate Phase 2
35 Mitogens Phase 1, Phase 2
36 Antimetabolites Phase 2
37 Ophthalmic Solutions Phase 2
38
Lenograstim Approved, Investigational 135968-09-1
39
Sargramostim Approved, Investigational 123774-72-1, 83869-56-1
40
Racepinephrine Approved 329-65-7 838
41
Epinephrine Approved, Vet_approved 51-43-4 5816
42
Hydrocortisone acetate Approved, Vet_approved 50-03-3
43
Hydrocortisone Approved, Vet_approved 50-23-7 5754
44
Clopidogrel Approved 120202-66-6, 113665-84-2 60606
45
Ticagrelor Approved 274693-27-5 9871419
46
Menthol Approved 2216-51-5 16666
47
Saxagliptin Approved 361442-04-8 11243969
48
Lamivudine Approved, Investigational 134678-17-4 60825
49
Adefovir dipivoxil Approved, Investigational 142340-99-6 60871
50
Dobutamine Approved 34368-04-2 36811

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
2 Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
3 Use of HA 330-II for Hemofiltration in Patients With Acute Liver Failure as a Bridge to Liver Transplantation: Clinical Evaluation Protocol. Recruiting NCT04243655 Phase 4 Standard medical treatment (SMT)
4 A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study Terminated NCT00896025 Phase 4 N-acetylcysteine
5 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure Completed NCT02786836 Phase 2, Phase 3 13C-Methacetin
6 Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen Completed NCT00004467 Phase 3 N-acetylcysteine (NAC);Placebo
7 A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. Completed NCT00248625 Phase 3 N-acetylcysteine;Placebo
8 Registry Protocol for Tracking the Incidence of Transplant, the Incidence and Type of Cancer, and Survival Rate of Subjects Participating in Protocol VTI-206 (NCT00973817) Withdrawn NCT01452295 Phase 2, Phase 3 ELAD (Extracorporeal Liver Assist System)
9 A Pivotal, Within Subject, Comparison of the LFT™ Dye Monitor System to the Indocyanine Green Dye (ICG) Serial Blood Plasma Disappearance Rate in Patients With Impaired and Non-Impaired Hepatic Function Withdrawn NCT02552901 Phase 3 0.1 mg/kg ICG Dose;0.5 mg/kg ICG dose
10 Infusion of Third-party Mesenchymal Stem Cells After Renal or Liver Transplantation. A Phase I-II, Open-label, Clinical Study Unknown status NCT01429038 Phase 1, Phase 2
11 Molecular Adsorbent Recirculating System (MARS®) for the Treatment of Patients With Hypoxic Hepatitis - a Prospective Randomized Controlled Clinical Study Unknown status NCT01690845 Phase 2
12 A Multicentre, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis and Early Stage Acute Liver Failure Unknown status NCT01318525 Phase 2 ALF-5755;Saline solution (0.9% NaCl)
13 Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure: A Double- Blind, Randomized, Placebo- Controlled Study Unknown status NCT00470314 Phase 2 L-Ornithine L-Aspartate
14 Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant and Late-Onset Hepatic Failure Unknown status NCT00225901 Phase 1, Phase 2 Recombinant human hepatocyte growth factor
15 A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury Completed NCT01548690 Phase 2 Ornithine Phenylacetate
16 Phase 2 Evaluation of the Vitagen Extracorporeal Liver Assist Device (ELAD) System in the Management of the Patients With Fulminant Hepatic Failure Completed NCT00030225 Phase 2
17 Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure Completed NCT01634230 Phase 2 OCR-002
18 Infusione Sistemica e Loco-regionale di N-Acetilcisteina Nel Prelievo di Fegato: Uno Studio Prospettico Randomizzato Controllato. Fase II. Completed NCT01394497 Phase 2 N-acetylcystein
19 Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) in Patients With Acute on Chronic Hepatitis (AOCH) Completed NCT00771446 Phase 1, Phase 2
20 A Phase 2b Study to Evaluate Safety and Efficacy of LifeLiver (Bio Artificial Liver) in Acute or Acute-on-Chronic Liver Failure Patients Waiting Emergent Liver Transplantation Recruiting NCT03882346 Phase 2
21 Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure Not yet recruiting NCT03863002 Phase 1, Phase 2
22 An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF) Terminated NCT01875874 Phase 2
23 A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure Terminated NCT01937130 Phase 2 IDN-6556
24 Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF) Withdrawn NCT00832728 Phase 2
25 The Safety Study of Stemchymal® (Allogeneic Adipose-Derived Mesenchymal Stem Cells) Treating on Acute Liver Failure - An Open-Label, Single-Center Phase I Trial Unknown status NCT03629015 Phase 1
26 A Randomized, Open-label, Single Dose, Crossover Design Phase I Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With 2 Formulations (Panadol and SafeTynadol) in Healthy Volunteers Completed NCT03451487 Phase 1 Panadol®;SafeTynadol®
27 Hepatocyte Transplantation for Acute Decompensated Liver Failure Withdrawn NCT01345565 Phase 1 human hepatocytes
28 Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure Unknown status NCT01582087
29 Safety and Efficacy of hiHep Bioartificial Liver Support System to Treat Acute Liver Failure Unknown status NCT03084198
30 G-CSF in Acute Liver Failure and Alcoholic Hepatitis - A Pilot Study Unknown status NCT01341951 Granulocyte colony stimulating factor
31 Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery Unknown status NCT01435421
32 Relationship of Serological Growth Factors and Hepatic Progenitor Cells in Acute Liver Failure Unknown status NCT01312220
33 Better Diagnostic Tools for Children and Adolescents With Acute Liver Failure and Chronic Liver Insufficiency Unknown status NCT03509194
34 A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China Unknown status NCT03281252
35 Right and Extended Right Hepatectomy in Patients Beyond 70 Years of Age - Liver Function and Outcome Unknown status NCT01471262
36 Clinical and Basic Study for Pediatric Liver Transplantation Unknown status NCT02503384
37 Cerebral Microdialysis in Patients With Fulminant Hepatic Failure Completed NCT00836420
38 Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure Completed NCT00245310
39 A Multi-Center Group to Study Acute Liver Failure in Children Completed NCT00986648
40 ASSESSMENT OF ADRENAL FUNCTION IN PATIENTS WITH ACUTE HEPATITIS USING CONCENTRATION OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL Completed NCT02859584
41 Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study) Completed NCT00488917
42 Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF). Completed NCT01946360
43 Frontal Electroencephalogram Variables Are Associated With Outcome and Stage of Hepatic Encephalopathy in Acute Liver Failure Completed NCT01878305
44 High Volume Plasma Exchange in Children With Acute Liver Failure and Acute on Chronic Liver Failure-A Prospective Pilot Study. Completed NCT02719210 Hypertonic 3% saline;Mannitol
45 High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure-A Prospective Randomized Pilot Trial Completed NCT02718079 Prophylactic Antibiotics;N-acetyl-L-cysteine
46 A Pharmacoepidemiological Study to Examine Patient Characteristics, Drug Utilization Pattern and Crude Incidence Rates of Selected Outcomes in New Users of Ticagrelor, Clopidogrel and Prasugrel in National Swedish Registries Completed NCT01276275 Risk of selected safety events
47 Pilot Trial on the Effect of Mild Hypothermia on Intracranial Pressure in Patients With Hyperacute Liver Failure Completed NCT00670124
48 The Effect of Prometheus (R) Liver Support Dialysis on Intracranial Pressure, Cerebral Oxidative Metabolism and Hemodynamics in Patients With Acute Liver Failure Completed NCT00655304
49 European Multicenter Plasma Exchange Trial (Empet): A Controlled, Open, Randomised, Multicenter Study In Patients With Acute Liver Failure Completed NCT00950508
50 Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF: A Randomized Open -Label Study Completed NCT02460510 Mannitol;3% hypertonic saline

Search NIH Clinical Center for Acute Liver Failure

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Liver Failure cell therapies at LifeMap Discovery.

Genetic Tests for Acute Liver Failure

Genetic tests related to Acute Liver Failure:

# Genetic test Affiliating Genes
1 Fulminant Hepatic Failure 29

Anatomical Context for Acute Liver Failure

MalaCards organs/tissues related to Acute Liver Failure:

40
Liver, Bone Marrow, Brain, Endothelial, Neutrophil, Myeloid, Cortex
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Acute Liver Failure:
# Tissue Anatomical CompartmentCell Relevance
1 Liver Liver Lobule Hepatocytes Affected by disease, potential therapeutic candidate

Publications for Acute Liver Failure

Articles related to Acute Liver Failure:

(show top 50) (show all 9486)
# Title Authors PMID Year
1
Vasoactive mediators in patients with acute liver failure treated with albumin dialysis. 54 61
19780957 2010
2
Genotype-confirmed alanine aminotransferase deficiency in a Chinese patient with acute liver failure: a potential diagnostic pitfall. 61 54
20025492 2010
3
Is it possible to gain extra waiting time to liver transplantation in acute liver failure patients using albumin dialysis? 61 54
19788458 2009
4
Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. 54 61
19788457 2009
5
[Establishment of pig acute liver failure model and the role of pig fibrinogen-like protein 2]. 54 61
19785959 2009
6
Translational research to identify clinical applications of hepatocyte growth factor. 54 61
19624764 2009
7
De novo mutations in POLG presenting with acute liver failure or encephalopathy. 61 54
19252446 2009
8
Acute liver failure: managing coagulopathy and the bleeding diathesis. 61 54
19460532 2009
9
A case-control study of single-pass albumin dialysis for acetaminophen-induced acute liver failure. 61 54
19590182 2009
10
[The significance of Gc-globulin in clinical practice]. 61 54
19002085 2008
11
Rapid diagnosis of Wilson disease in acute liver failure: no more waiting for the ceruloplasmin level? 61 54
18821595 2008
12
Predictive value of serum-soluble CD154 in fulminant hepatic failure. 61 54
18652769 2008
13
Acute hepatitis C. 54 61
18657711 2008
14
Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. 54 61
18294203 2008
15
Acetaminophen-induced acute liver failure treated with single-pass albumin dialysis: report of a case. 61 54
18609519 2008
16
Alpers syndrome with prominent white matter changes. 54 61
17923349 2008
17
Cytokine profiles in acute liver failure treated with albumin dialysis. 54 61
18181803 2008
18
Serum apoptosis markers in acute liver failure: a pilot study. 54 61
17967565 2007
19
Albumin dialysis: an update. 54 61
18089976 2007
20
[Establishment of a D-galactosamine/lipopolysaccharide induced acute-on-chronic liver failure model in rats]. 54 61
17963606 2007
21
Actin-free Gc globulin: a rapidly assessed biomarker of organ dysfunction in acute liver failure and cirrhosis. 54 61
17763400 2007
22
Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. 54 61
17439518 2007
23
Protein chemical characterization of Gc globulin (vitamin D-binding protein) isoforms; Gc-1f, Gc-1s and Gc-2. 61 54
17360250 2007
24
Serum hepatocyte growth factor and vascular endothelial growth factor in children with acute liver failure. 61 54
17255836 2007
25
Acute liver failure due to leptospirosis successfully treated with MARS (molecular adsorbent recirculating system) dialysis. 61 54
17203354 2007
26
Drug-induced liver injury. 54 61
17408305 2007
27
Comparison of rocket and crossed immuno-electrophoresis assays for determination of the level of actin complexing of Gc globulin. 61 54
17852808 2007
28
The acidifying effect of lactate is neutralized by the alkalinizing effect of hypoalbuminemia in non-paracetamol-induced acute liver failure. 61 54
16750869 2006
29
Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. 54 61
16871541 2006
30
Ornithine transcarbamoylase deficiency presenting with acute liver failure. 61 54
16802108 2006
31
Bridging to transplantation in acute liver failure in a 7-month-old infant. 54 61
16810489 2006
32
Large-scale purification and characterization of non-glycosylated Gc globulin (vitamin D-binding protein) from plasma fraction IV. 61 54
16402919 2006
33
Ratio of circulating follistatin and activin A reflects the severity of acute liver injury and prognosis in patients with acute liver failure. 54 61
16509861 2006
34
Development of a rapid semi-quantitative immunochromatographic assay for serum hepatocyte growth factor and its usefulness in acute liver failure. 54 61
16293443 2005
35
Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. 54 61
16261428 2005
36
The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. 54 61
16182740 2005
37
Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom. 54 61
15861019 2005
38
Transplantation of human hepatocytes cultured with deleted variant of hepatocyte growth factor prolongs the survival of mice with acute liver failure. 61 54
15912107 2005
39
Mild hypothermia prevents brain edema and attenuates up-regulation of the astrocytic benzodiazepine receptor in experimental acute liver failure. 54 61
15826719 2005
40
The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation. 54 61
15848631 2005
41
Intraoperative blood transfusion requirement is the main determinant of early surgical re-intervention after orthotopic liver transplantation. 61 54
15717214 2005
42
[Intensive care medicine 2004]. 54 61
15490076 2004
43
Anti-inflammatory effects of hepatocyte growth factor: induction of interleukin-1 receptor antagonist. 61 54
15627638 2004
44
Evaluation of serum albumin utilization in inpatient at a private hospital in Bangkok. 54 61
15340186 2004
45
[Use of albumin dialysis with the MARS device to treat a case acute liver failure after partial hepatic resection]. 54 61
15274801 2004
46
[Albumin dialysis MARS (Molecular Adsorbent Recirculating System) as a bridge for liver transplantation in acute liver failure. Report of three cases]. 61 54
15279147 2004
47
Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs. 61 54
14735236 2004
48
Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. 61 54
14596869 2003
49
Changes in serum levels of hepatocyte growth factor in patients undergoing adult-to-adult living-donor liver transplantation. 54 61
14688531 2003
50
Up-regulation of hepatocyte growth factor caused by an over-expression of transforming growth factor beta, in the rat model of fulminant hepatic failure. 61 54
14697288 2003

Variations for Acute Liver Failure

ClinVar genetic disease variations for Acute Liver Failure:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RINT1 NM_021930.6(RINT1):c.1109T>C (p.Leu370Pro) SNV Pathogenic 599396 rs1562849964 7:105190709-105190709 7:105550262-105550262
2 RINT1 NM_021930.6(RINT1):c.1333+1G>A SNV Pathogenic 547947 rs375350359 7:105190934-105190934 7:105550487-105550487
3 POLG2 NM_007215.4(POLG2):c.544C>T (p.Arg182Trp) SNV Likely pathogenic 252958 rs886037843 17:62492543-62492543 17:64496425-64496425
4 MT-CO3 NC_012920.1:m.9355A>T SNV Uncertain significance 523307 rs1556423663 MT:9355-9355 MT:9355-9355

Expression for Acute Liver Failure

Search GEO for disease gene expression data for Acute Liver Failure.

Pathways for Acute Liver Failure

GO Terms for Acute Liver Failure

Cellular components related to Acute Liver Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.33 GC F2 ALB
2 Dsl1/NZR complex GO:0070939 8.96 RINT1 NBAS
3 gamma DNA polymerase complex GO:0005760 8.62 POLG2 POLG

Biological processes related to Acute Liver Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA biosynthetic process GO:0071897 9.37 POLG2 POLG
2 positive regulation of reactive oxygen species metabolic process GO:2000379 9.32 TSPO F2
3 anion transport GO:0006820 9.26 TSPO SLC17A5
4 DNA-dependent DNA replication GO:0006261 9.16 POLG2 POLG
5 transport GO:0006810 8.96 GC ALB
6 mitochondrial DNA replication GO:0006264 8.62 POLG2 POLG

Molecular functions related to Acute Liver Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-directed DNA polymerase activity GO:0003887 8.62 POLG2 POLG

Sources for Acute Liver Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....